|
시장보고서
상품코드
2036469
미세잔존질환 검사 시장 규모, 점유율 및 성장 분석 : 검사 유형별, 검체 유형별, 최종사용자별, 용도별, 지역별 - 업계 예측(2026-2033년)Minimal Residual Disease Testing Market Size, Share, and Growth Analysis, By Testing Types (Cell-Based Tests, Molecular Tests), By Sample Types, By End Users, By Application, By Region - Industry Forecast 2026-2033 |
||||||
세계의 미세잔존질환(MRD) 검사 시장 규모는 2024년에 66억 달러로 평가되며, 2025년 69억 5,000만 달러에서 2033년까지 105억 1,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 5.3%로 성장할 것으로 전망되고 있습니다.
세계의 미세잔존질환(MRD) 검사 시장은 치료 후 남아있는 미세한 암세포를 식별하는 고감도 검사법에 초점을 맞추고 있으며, 이는 재발 예측 및 치료법 선택에 있으며, 매우 중요합니다. 시장 상황은 기존의 유세포분석이나 PCR 방법에서 민감도와 표준화를 향상시키는 첨단 차세대 시퀀싱 및 디지털 PCR 기술로 전환되고 있습니다. 학계와 민간기업의 협력으로 MRD 기반 치료 시험이 성공적으로 진행되면서 도입 확대와 보험사 측의 관심이 높아지고 있습니다. 규제 당국의 승인과 보험 환급은 MRD 검사가 임상 진료에 통합되는 것을 촉진하는 필수적인 성장 요인입니다. 또한 AI의 혁신을 통해 잡음과 진정한 신호를 구별하고, 돌연변이 검출의 정확도를 높이고, 결과를 더 빠르게 처리함으로써 정확도를 더욱 향상시키고 있습니다. 이를 통해 임상적 의사결정을 개선하고 MRD 검사 솔루션의 시장 수용성을 더욱 확대할 수 있게 되었습니다.
세계의 미세잔존질환(MRD) 검사 시장의 성장요인
세계의 미세잔존질환(MRD) 검사 시장은 검사의 민감도와 특이성 향상에 힘입어 크게 성장하고 있습니다. 이를 통해 기존에는 감지할 수 없었던 미세한 잔존 병변의 신호를 감지할 수 있게 되었습니다. 미세한 병변의 흔적을 찾아내는 능력이 향상되면서 MRD 검사 결과에 대한 임상적 신뢰도가 높아졌고, 그 결과 임상현장에서의 채택이 더욱 확대되고 있습니다. 위음성을 최소화하고 질병 모니터링의 정확성을 향상시키는 이러한 기술 혁신으로 인해 임상의들은 치료 의사결정 과정에 MRD 검사를 점점 더 많이 도입하고 있습니다. 또한 장비의 고도화 및 분자 분석의 정교화는 광범위한 연구 응용 및 검증 연구를 위한 길을 열어주고, 진단약 개발자와 의료 서비스 제공자 간의 협력을 촉진하여 MRD 검사 솔루션에 대한 시장 수요를 자극하고 있습니다.
세계의 미세잔존질환(MRD) 검사 시장 억제요인
전 세계 미세잔존질환(MRD) 검사 시장은 고급 MRD 분석 및 전문 장비에 대한 높은 비용, 숙련된 검사 기술자의 필요성 등의 요인으로 인해 큰 도전에 직면해 있습니다. 이러한 재정적 제약은 예산이 한정된 의료 기관이 MRD 검사 도입을 주저하게 만드는 원인이 될 수 있습니다. 특히 비용 대비 효과가 불분명한 경우, 검사 1회당 고가의 비용이 일상적인 적용을 주저하게 만들 수 있기 때문입니다. 이러한 상황은 MRD 검사 이용을 자금력이 있는 기관으로 제한함으로써 시장 성장을 저해하고, 결과적으로 다양한 의료 현장에서의 광범위한 도입을 방해하며, 소규모 검사실과 의료 서비스 제공자가 MRD 검사 역량에 투자할 기회를 감소시킬 수 있습니다.
세계의 미세잔존질환(MRD) 검사 시장 동향
전 세계 미세잔존질환(MRD) 검사 시장에서는 환자 인근 및 지역사회 기반 검사 솔루션의 빠른 도입으로 검사 분산화 추세가 두드러지게 나타나고 있습니다. 이러한 변화는 의료진이 보다 신속한 치료 방침 결정과 환자 경과 관찰을 위해 임상 접근성과 모니터링 능력을 향상시키고 있습니다. 워크플로우의 효율화와 첨단 검체 안정화 기술의 혁신과 더불어, 표준 검사기관과 지역 클리닉과의 협력을 통해 기존 3차 의료기관 이외의 장소에서의 검사 제공이 촉진되고 있습니다. 이러한 추세는 분자 수준에서 재발을 더 자주 감시하고 조기에 발견하는 동시에 편의성, 치료 순응도, 개별화된 치료 조정을 우선시하는 원격의료 노력 및 환자 중심 치료 모델과 원활하게 통합되어 엄격한 분석 기준을 유지하면서 분자 수준에서 재발을 더 자주 감시하고 조기에 발견할 수 있도록 합니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 미세잔존질환 검사 시장 규모 : 검사 유형별
세계의 미세잔존질환 검사 시장 규모 : 검체 유형별
세계의 미세잔존질환 검사 시장 규모 : 최종사용자별
세계의 미세잔존질환 검사 시장 규모 : 용도별
세계의 미세잔존질환 검사 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.05.27Global Minimal Residual Disease Testing Market size was valued at USD 6.6 Billion in 2024 and is poised to grow from USD 6.95 Billion in 2025 to USD 10.51 Billion by 2033, growing at a CAGR of 5.3% during the forecast period (2026-2033).
The global minimal residual disease (MRD) testing market focuses on highly sensitive assays that identify microscopic cancer cell remnants post-treatment, which are crucial for predicting relapse and informing therapy choices. The landscape has transitioned from traditional flow cytometry and PCR methods to advanced next-generation sequencing and digital PCR technologies that enhance sensitivity and standardization. Collaborations between academic and commercial entities have led to successful MRD-guided treatment trials, boosting adoption and payer interest. Regulatory approval and reimbursement are essential growth drivers, encouraging the integration of MRD testing into clinical care. Additionally, AI innovations further refine accuracy by distinguishing true signals from noise, enhancing variant detection, and expediting results, thus improving clinical decision-making and fostering broader market acceptance of MRD testing solutions.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Minimal Residual Disease Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Minimal Residual Disease Testing Market Segments Analysis
Global minimal residual disease testing market is segmented by testing types, sample types, end users, application and region. Based on testing types, the market is segmented into Cell-Based Tests and Molecular Tests. Based on sample types, the market is segmented into Blood Samples and Bone Marrow Samples. Based on end users, the market is segmented into Hospitals and Diagnostic Laboratories. Based on application, the market is segmented into Hematological Malignancies, Solid Tumors and Autoimmune Disorders. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Minimal Residual Disease Testing Market
The Global Minimal Residual Disease Testing market is being significantly propelled forward by advancements in assay sensitivity and specificity, which allow for the detection of previously undetectable residual disease signals. This heightened ability to identify minute traces of disease enhances clinical confidence in MRD results, thereby fostering broader clinical adoption. By minimizing false negatives and improving disease monitoring accuracy, these technological innovations lead clinicians to increasingly incorporate MRD testing into their treatment decision-making processes. Additionally, enhanced instrumentation and sophisticated molecular assays open avenues for extensive research applications and validation studies, driving collaborations between diagnostics developers and healthcare providers that stimulate market demand for MRD testing solutions.
Restraints in the Global Minimal Residual Disease Testing Market
The Global Minimal Residual Disease (MRD) Testing market faces significant challenges due to the high costs associated with advanced MRD assays, specialized equipment, and the necessity for trained laboratory personnel. These financial constraints can dissuade healthcare facilities with limited budgets from adopting MRD testing, as the expensive per-test rates may lead to hesitation in its routine application, particularly where cost-effectiveness is unclear. This situation can stifle market growth by confining the use of MRD tests to well-funded centers, thus hindering broader implementation across various healthcare settings and diminishing opportunities for smaller laboratories and providers to invest in MRD testing capabilities.
Market Trends of the Global Minimal Residual Disease Testing Market
The Global Minimal Residual Disease Testing market is witnessing a significant trend towards decentralized testing, characterized by the rapid adoption of near-patient and community-based testing solutions. This shift enhances clinical access and monitoring capabilities as healthcare providers aim for quicker therapeutic decision-making and patient follow-up. Innovations in streamlined workflows and advanced sample stabilization techniques, coupled with collaborations between reference laboratories and local clinics, are facilitating the distribution of testing beyond traditional tertiary care settings. This trend promotes more frequent surveillance and early detection of molecular relapses, while seamlessly integrating with telehealth initiatives and patient-centric care models that prioritize convenience, adherence, and personalized treatment adjustments, all while maintaining rigorous analytical standards.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Minimal Residual Disease Testing Market Size by Testing Types & CAGR (2026-2033)
- Market Overview
- Cell-Based Tests
- Molecular Tests
- Next-Generation Sequencing
- Digital PCR
Global Minimal Residual Disease Testing Market Size by Sample Types & CAGR (2026-2033)
- Market Overview
- Blood Samples
- Bone Marrow Samples
Global Minimal Residual Disease Testing Market Size by End Users & CAGR (2026-2033)
- Market Overview
- Hospitals
- Diagnostic Laboratories
Global Minimal Residual Disease Testing Market Size by Application & CAGR (2026-2033)
- Market Overview
- Hematological Malignancies
- Solid Tumors
- Autoimmune Disorders
Global Minimal Residual Disease Testing Market Size & CAGR (2026-2033)
- North America (Testing Types, Sample Types, End Users, Application)
- US
- Canada
- Europe (Testing Types, Sample Types, End Users, Application)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Testing Types, Sample Types, End Users, Application)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Testing Types, Sample Types, End Users, Application)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Testing Types, Sample Types, End Users, Application)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- exact Sciences Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioTrack
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ArcherDX
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adaptive Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- OncoOne
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Caredx
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NeoGenomics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Freenome
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Trovagene
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Foundation Medicine
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genetic Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Illumina
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Tempus
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GRAIL
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- DiaSorin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Siemens Healthineers
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
